Wave Life Sciences Shares Rise on FDA Support for AATD Therapy Registration

Key Facts

Wave Life Sciences announced FDA support for its registrational plans regarding an Alpha-1 antitrypsin deficiency (AATD) therapy. Seeking Alpha reported that the company secured a favorable path forward for the registration of WVE-006, an experimental treatment for the rare genetic disorder.

Shares of the company rose during trading on October 1, 2026, as the FDA's backing provided a clear regulatory roadmap and reduced uncertainty for the lead therapy candidate. The announcement followed a recent meeting with the regulator to discuss the clinical requirements for the therapy's registration.